PDCD1 and glioma: Additionally, clinical research indicates that the therapeutic efficacy of pembrolizumab, an anti-programmed cell death protein 1 (PD1) antibody, is confined to glioma patients with specific types of DNA mismatch repair deficiencies (Yang et al., 2022).